Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma

IF 2.3 3区 生物学 Q3 BIOCHEMICAL RESEARCH METHODS
Qiang Huang , Mengyou Ji , Feiran Li , Yufeng Li , Xuehua Zhou , Chi-yao Hsueh , Liang Zhou
{"title":"Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma","authors":"Qiang Huang ,&nbsp;Mengyou Ji ,&nbsp;Feiran Li ,&nbsp;Yufeng Li ,&nbsp;Xuehua Zhou ,&nbsp;Chi-yao Hsueh ,&nbsp;Liang Zhou","doi":"10.1016/j.mcp.2023.101895","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Circulating cell-free DNA (cfDNA) and vascular endothelial growth factor-C (VEGF-C) can be utilized to detect cancer and predict its prognosis. However, their potential application in laryngeal squamous cell carcinoma (LSCC) is unclear.</p></div><div><h3>Purpose</h3><p>This study aimed to identify the diagnostic and prognostic value of cfDNA and VEGF-C in LSCC patients<strong>.</strong></p></div><div><h3>Methods</h3><p>The plasma cfDNA of 148 LSCC patients and 43 non-tumor patients were isolated. Quantitative real-time PCR (qRT-PCR) was performed to assess long and short DNA fragments in plasma by amplifying the ALU repeats. ALU-qPCR results (ALU247/ALU115) were used to calculate cfDNA integrity index. Vascular endothelial growth factor-C (VEGF-C) level was detected by ELISA assay. Correlation between cfDNA and clinical features was analyzed. For detecting the sensitivity and specificity of cfDNA and VEGF-C alone or in combination for diagnosing LSCC, receiver operator characteristic (ROC) was established. For evaluating the overall survival (OS) of LSCC, Kaplan-Meier curves were established.</p></div><div><h3>Results</h3><p>LSCC patients had significantly higher levels of plasma cfDNA (ALU115, ALU247, and cfDNA integrity index) and VEGF-C than those without cancer (p &lt; 0.05), showing area under the curve (AUC) values of 0.79, 0.74, 0.62 and 0.80, when cutoff value was correspondingly defined at 2.14 ng/mL, 1.39 ng/mL, 0.73 and 412.90 pg/mL, respectively. The AUC for distinguishing LSCC patients from non-tumor patients by plasma cfDNA combined with VEGF-C was 0.89 (95% CI: 0.83–0.94). A significant correlation was found between plasma cfDNA levels and Ki-67, tumor size, pT stage, and smoking history (p &lt; 0.05). Based on survival analysis, low VEGF-C concentration groups had longer OS than those with high VEGF-C concentration (p = 0.02).</p></div><div><h3>Conclusion</h3><p>Indicators such as plasma cfDNA and VEGF-C may be used to diagnose and monitor LSCC for its noninvasiveness and rapid accessibility.</p></div>","PeriodicalId":49799,"journal":{"name":"Molecular and Cellular Probes","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and Cellular Probes","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S089085082300004X","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 2

Abstract

Background

Circulating cell-free DNA (cfDNA) and vascular endothelial growth factor-C (VEGF-C) can be utilized to detect cancer and predict its prognosis. However, their potential application in laryngeal squamous cell carcinoma (LSCC) is unclear.

Purpose

This study aimed to identify the diagnostic and prognostic value of cfDNA and VEGF-C in LSCC patients.

Methods

The plasma cfDNA of 148 LSCC patients and 43 non-tumor patients were isolated. Quantitative real-time PCR (qRT-PCR) was performed to assess long and short DNA fragments in plasma by amplifying the ALU repeats. ALU-qPCR results (ALU247/ALU115) were used to calculate cfDNA integrity index. Vascular endothelial growth factor-C (VEGF-C) level was detected by ELISA assay. Correlation between cfDNA and clinical features was analyzed. For detecting the sensitivity and specificity of cfDNA and VEGF-C alone or in combination for diagnosing LSCC, receiver operator characteristic (ROC) was established. For evaluating the overall survival (OS) of LSCC, Kaplan-Meier curves were established.

Results

LSCC patients had significantly higher levels of plasma cfDNA (ALU115, ALU247, and cfDNA integrity index) and VEGF-C than those without cancer (p < 0.05), showing area under the curve (AUC) values of 0.79, 0.74, 0.62 and 0.80, when cutoff value was correspondingly defined at 2.14 ng/mL, 1.39 ng/mL, 0.73 and 412.90 pg/mL, respectively. The AUC for distinguishing LSCC patients from non-tumor patients by plasma cfDNA combined with VEGF-C was 0.89 (95% CI: 0.83–0.94). A significant correlation was found between plasma cfDNA levels and Ki-67, tumor size, pT stage, and smoking history (p < 0.05). Based on survival analysis, low VEGF-C concentration groups had longer OS than those with high VEGF-C concentration (p = 0.02).

Conclusion

Indicators such as plasma cfDNA and VEGF-C may be used to diagnose and monitor LSCC for its noninvasiveness and rapid accessibility.

血浆无细胞DNA联合VEGF-C对喉鳞状细胞癌的诊断和预后价值
背景循环无细胞DNA(cfDNA)和血管内皮生长因子-C(VEGF-C)可用于检测癌症并预测其预后。然而,它们在喉鳞状细胞癌(LSCC)中的潜在应用尚不清楚。目的本研究旨在确定cfDNA和VEGF-C在LSCC患者中的诊断和预后价值。方法分离148例LSCC患者和43例非肿瘤患者的血浆cfDNA。通过扩增ALU重复序列,进行定量实时PCR(qRT-PCR)以评估血浆中的长短DNA片段。ALU-qPCR结果(ALU247/ALU115)用于计算cfDNA完整性指数。ELISA法检测血管内皮生长因子-C(VEGF-C)水平。分析cfDNA与临床特征的相关性。为了检测cfDNA和VEGF-C单独或联合用于诊断LSCC的敏感性和特异性,建立了受体操作特性(ROC)。为了评估LSCC的总生存率,建立了Kaplan-Meier曲线。结果LSCC患者的血浆cfDNA(ALU115、ALU247和cfDNA完整性指数)和VEGF-C水平显著高于癌症患者(p<0.05),曲线下面积(AUC)分别为0.79、0.74、0.62和0.80,临界值分别为2.14 ng/mL、1.39 ng/mL、0.73和412.90 pg/mL。血浆cfDNA联合VEGF-C区分LSCC患者和非肿瘤患者的AUC为0.89(95%CI:0.83-0.94)。发现血浆cfDNA水平与Ki-67、肿瘤大小、pT分期和吸烟史之间存在显著相关性(p<;0.05)。基于生存分析,结论血浆cfDNA和VEGF-C等指标可用于诊断和监测LSCC的无侵袭性和快速可及性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular and Cellular Probes
Molecular and Cellular Probes 生物-生化研究方法
CiteScore
6.80
自引率
0.00%
发文量
52
审稿时长
16 days
期刊介绍: MCP - Advancing biology through–omics and bioinformatic technologies wants to capture outcomes from the current revolution in molecular technologies and sciences. The journal has broadened its scope and embraces any high quality research papers, reviews and opinions in areas including, but not limited to, molecular biology, cell biology, biochemistry, immunology, physiology, epidemiology, ecology, virology, microbiology, parasitology, genetics, evolutionary biology, genomics (including metagenomics), bioinformatics, proteomics, metabolomics, glycomics, and lipidomics. Submissions with a technology-driven focus on understanding normal biological or disease processes as well as conceptual advances and paradigm shifts are particularly encouraged. The Editors welcome fundamental or applied research areas; pre-submission enquiries about advanced draft manuscripts are welcomed. Top quality research and manuscripts will be fast-tracked.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信